Response to the publication by Ueberall and Mueller-Schwefe
Gonçalo S Duarte,1–3 João Santos,3 João Costa1–4
1Clinical Pharmacology and Therapeutics Laboratory, Faculdade de Medicina, Universidade de Lisboa, 2Clinical Pharmacology Unit, Instituto de Medicina Molecular, 3Center for Evidence Based Medicine, Faculdade de Medicina, Universidade de Lisboa, 4Cochrane Portugal, Lisboa, Portugal
While updating our Cochrane review on tapentadol for chronic musculoskeletal pain,1 we found a study by Ueberall and Mueller-Schwefe.2 It passed the initial screening phase by using words such as “blinded” and “randomly”, methodologically positive characteristics most often seen in randomized controlled trials (RCTs). On further analysis, we found that it is not an RCT and therefore not eligible for our Cochrane review. We nonetheless remained interested, since the authors clearly made methodological options that, despite sounding pondered, rigorous, and methodologically desirable, in fact add little to nothing in terms of quality or rigor. In fact, this quasi-rigor can be fully appreciated when assessing the study using the Cochrane model for risk of bias in non-randomized studies of interventions.3
View the original paper by Ueberall and Mueller-Schwefe.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]